(The drug is priced at about $1,350 per month and doctors who are taking payments from Novo Nordisk have taken to the media - typically without disclosure of their financial interests - to bemoan the lack of insurance coverage.) I predict that between now and then Novo Nordisk will not be in any hurry to put out studies with longer-term weight loss or side effect information
Translating evidence to optimize patient care using GRADE
Less fat correlates with lower blood glucose levels, fewer heart attacks, less weight on aging hip and knee joints, improvement in fatty liver disease, delayed progression of diabetes-related kidney disease and more energy for day-to-day activities
Reviewing dose consistency, increasing protein, tightening up eating habits for a short period, improving sleep, and managing stress can help restart progress
Many of our patients find that GLP-1 Daily Support helps manage the transition as their bodies adjust to new treatments